Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Nanobiotix
  6. News
  7. Press Releases
    NANO   FR0011341205

NANOBIOTIX

(NANO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société NANOBIOTIX
05/18CORRECTING AND REPLACING : NANOBIOTIX Provides First Quarter Operational and Financial Upd..
BU
05/18NANOBIOTIX Provides First Quarter Operational and Financial Update
BU
05/17NANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022
BU
05/11NANOBIOTIX to Participate in Two Upcoming Investor Conferences
BU
05/04NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022
BU
05/02New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022..
BU
04/11NANOBOTIX : New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation v..
PU
04/11NANOBOTIX :  New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation ..
BU
04/11NANOBIOTIX : Press Release, dated April 08, 2022 - Form 6-K
PU
04/08NANOBIOTIX Announces Filing of the 2021 Universal Registration Document and the 2021 An..
BU
04/08NANOBIOTIX : Form 20-f/a
PU
03/30NANOBIOTIX : Inside Information / Other news releases
PU
03/30NANOBIOTIX : Provides Business Update and Reports Full Year 2021 Financial Results - Form ..
PU
03/30 NANOBIOTIX Provides Business Update and Reports Full Year 2021 Financial Results
BU
03/16NANOBIOTIX : to Announce Full Year 2021 Financial Results on March 30, 2022 - Form 6-K
PU
03/16NANOBIOTIX to Announce Full Year 2021 Financial Results on March 30, 2022
BU
02/10NANOBIOTIX : Inside Information / Other news releases
PU
02/09NANOBIOTIX : Announces Publication of New Clinical Case Study Highlighting First Patient E..
PU
02/09Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient ..
BU
02/04NANOBIOTIX : OPERATING AND FINANCIAL REVIEW AND PROSPECTS - Form 6-K
PU
01/26NANOBIOTIX : Announces Publication of New Preclinical Immunotherapy Data Showcasing the Co..
PU
01/26NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the C..
BU
01/10NANOBIOTIX : Provides Corporate Update and Highlights Key 2022 Milestone Targets - Form 6-..
PU
01/10NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets
BU
01/05NANOBIOTIX : Announces First Patient Enrolled in NANORAY-312 Global Phase III Registration..
PU
01/05NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registratio..
BU
01/04Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 202..
BU
2021NANOBIOTIX : to Present at the 4th Annual Evercore ISI HealthCONx Conference - Form 6-K
PU
2021NANOBIOTIX to Present at the 4th Annual Evercore ISI HealthCONx Conference
BU
2021NANOBIOTIX Announces New Preclinical Data Highlighting NBTXR3 Immune Priming and Checkp..
PU
2021NANOBIOTIX Announces New Preclinical Data Highlighting NBTXR3 Immune Priming and Checkp..
BU
2021NANOBIOTIX to Participate in a Fireside Chat at the Jefferies London Healthcare Confere..
PU
2021NANOBIOTIX to Participate in a Fireside Chat at the Jefferies London Healthcare Confere..
BU
2021NANOBIOTIX : Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Fra..
PU
2021NANOBIOTIX : Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Fra..
BU
2021NANOBIOTIX : Provides Third Quarter Operational and Financial Update - Form 6-K
PU
2021NANOBIOTIX : Provides Third Quarter Operational and Financial Update
BU
2021NANOBIOTIX : In accordance with Articles L.233-8 II of the French Commercial Code and 223-..
PU
2021NANOBIOTIX : to Present First Survival Data From Priority Head and Neck Cancer Program Amo..
PU
2021NANOBIOTIX : to Present First Survival Data From Priority Head and Neck Cancer Program Amo..
BU
2021NANOBIOTIX : Announces Red Journal Publication of Preclinical Data Showing Radioenhancer N..
PU
2021NANOBIOTIX : Announces Red Journal Publication of Preclinical Data Showing Radioenhancer N..
BU
2021NANOBIOTIX : In accordance with Articles L.233-8 II of the French Commercial Code and 223-..
PU
2021NANOBIOTIX : LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Form 6-K)
PU
2021NANOBIOTIX : PROVIDES BUSINESS UPDATE AND REPORTS FINANCIAL RESULTS FOR THE FIRST HALF OF ..
PU
2021NANOBIOTIX S A : Provides Business Update and Reports Financial Results for the First Half..
BU
2021NANOBIOTIX : TO PRESENT AT THE H.C. WAINWRIGHT 23rd ANNUAL GLOBAL INVESTMENT CONFERENCE (F..
PU
2021NANOBIOTIX S A : to Present at the H.C. Wainwright 23rd Annual Global Investment Conferenc..
BU
2021NANOBIOTIX : PROVIDES SECOND QUARTER OPERATIONAL AND FINANCIAL UPDATE (Form 6-K)
PU
2021NANOBIOTIX S A : Provides Second Quarter Operational and Financial Update
BU
2021NANOBIOTIX : ANNOUNCES INITIATION OF NEW CLINICAL STUDY EVALUATING NBTXR3 IN LUNG CANCER (..
PU
2021NANOBIOTIX : Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer
BU
2021NANOBIOTIX : TO HOST VIRTUAL KOL EVENT DISCUSSING POTENTIAL FIRST-IN-CLASS RADIOENHANCER N..
PU
2021NANOBIOTIX : to Host Virtual KOL Event Discussing Potential First-in-Class Radioenhancer N..
BU
2021NANOBIOTIX : REPORTS NEW DATA FOR POTENTIAL FIRST-IN-CLASS RADIOENHANCER NBTXR3 IN COMBINA..
PU
2021NANOBIOTIX : Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combina..
BU
2021NANOBIOTIX : ANNOUNCES THE APPOINTMENT OF BART VAN RHIJN AS CHIEF FINANCIAL OFFICER AND ME..
PU
2021NANOBIOTIX : Announces the Appointment of Bart Van Rhijn as Chief Financial Officer and Me..
BU
2021NANOBIOTIX : TO PARTICIPATE IN FIRESIDE CHAT AT THE JEFFERIES VIRTUAL HEALTHCARE CONFERENC..
PU
2021NANOBIOTIX : to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conferenc..
BU
2021NANOBIOTIX : ANNOUNCES THE APPOINTMENT OF DR. GARY PHILLIPS AS CHAIRMAN OF THE NANOBIOTIX ..
PU
2021NANOBIOTIX : Announces the Appointment of Dr. Gary Phillips as Chairman of the Nanobiotix ..
BU
2021NANOBIOTIX : ANNOUNCES UPDATED RESULTS FROM PRIORITY PATHWAYS IN HEAD AND NECK CANCER AND ..
PU
2021CORRECTING AND REPLACING : Nanobiotix Announces Updated Results From Priority Pathways in ..
BU
2021NANOBIOTIX : ANNOUNCES UPDATED RESULTS FROM PRIORITY PATHWAYS IN HEAD AND NECK CANCER AND ..
PU
2021NANOBIOTIX S A : CORRECTING and REPLACING Nanobiotix Announces Updated Results From Priori..
BU
2021NANOBIOTIX : Announces Updated Results From Priority Pathways In Head And Neck Cancer And ..
PU
2021NANOBIOTIX : to Present at the UBS Global Healthcare Virtual Conference (Form 6-K)
PU
2021NANOBIOTIX : to Present at the UBS Global Healthcare Virtual Conference
BU
2021NANOBIOTIX : Partners With LianBio to Develop and Commercialize Potential First-in-Class R..
BU
2021NANOBIOTIX : PARTNERS WITH LIANBIO TO DEVELOP AND COMMERCIALIZE POTENTIAL FIRST-IN-CLASS R..
PU
2021NANOBIOTIX : Announces first quarter operational and financial updates
PU
2021NANOBIOTIX : Rapport sur les comptes annuels - AGM 2021
PU
2021NANOBIOTIX : Voting Results for the Annual Combined General Meeting of Shareholders
PU
2021NANOBIOTIX : to Present Four Posters Including Updates From Priority Head and Neck Cancer ..
BU
1  2  3  4  5Next
Official Publications
05/181st quarter results 
05/18Mixed general Shareholders meeting 
05/181st quarter results 
04/30Monthly statement on outstanding equity sh.. 
04/30Monthly statement on outstanding equity sh.. 
04/14Crossing thresholds 
Upcoming event on NANOBIOTIX
06/03/22American Society of Clinical Oncology Meeting - Abstract No. TPS6110
Upcoming sector events
07/26/22IQVIA HOLDINGS INC. : Interim 2022 Earnings Release (Projected)
07/27/22LONZA GROUP AG : Interim 2022 Earnings Release (Projected)
07/28/22SEAGEN INC. : Interim 2022 Earnings Release (Projected)
08/10/22MODERNA, INC. : Interim 2022 Earnings Release (Projected)
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Other Biotechnology & Medical Research